Loading
Myriad Genetics' whole-genome blood test for leftover cancer, launched in 2026 for breast cancer and extended to bowel and kidney cancer.
Myriad Genetics launched Precise MRD on 2 March 2026 with a select number of oncology practices for patients with breast cancer, describing whole-genome sequencing of the tumour to build a personalised assay with detection of ctDNA down to one part per million. On 23 June 2026 it broadened availability to patients being treated or followed for breast, colorectal and renal cancer, stating that the panel holds up to 1,000 patient-specific variants, and announced publication of the MONITOR-Breast study of ctDNA during neoadjuvant therapy in Future Oncology.
Whole-genome sequencing of tumour tissue builds a panel of up to 1,000 patient-specific variants that is tracked in plasma, with stated detection down to one part per million.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Precise MRD" OR ABSTRACT:"Precise MRD" OR TITLE:"Myriad Precise MRD" OR ABSTRACT:"Myriad Precise MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Precise MRD, not a curated reading list.
Shares NeXT Personal Dx, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares NeXT Personal Dx, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares NeXT Personal Dx, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/